Doseology Sciences Inc (DOSEF) Fair Value & Analysis
Healthcare · US · Market cap $898K
Fair value as of: Jun 26, 2026
Analysis
Doseology Sciences Inc (DOSEF) currently trades at $0.1121, while our model-based Fair Value estimate is $0.1800 — implying the stock looks roughly 60.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Doseology Sciences Inc., through its subsidiary, Dose Labs Inc., engages in the research, development, and sale of functional mushroom products with a focus on mental health research in Canada. The company also offers medicinal mushroom products, including tinctures. It sells its products online through doseology.com and e-commerce platforms, as well as through various retail chains and distributors. The company was formerly known as Pcybin Therapeutic Inc. and changed its name to Doseology Sciences Inc. in January 2020. Doseology Sciences Inc. was incorporated in 2019 and is based in Kelowna, Canada.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Doseology Sciences Inc (DOSEF) undervalued?
What is the fair value of DOSEF?
What is the quality score of DOSEF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.